Friday, March 24, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Army Conducting Market Research on Next-Generation Diagnostics for Biothreats

by Global Biodefense Staff
May 16, 2013

JPEO CBD - Joint Program Executive Office for Chemical and Biological DefenseThe Chemical Biological Medical Systems – Biosurveillance (CBMS-BSV) is soliciting information to support strategic planning for development of the Next Generation Diagnostics System (NGDS) acquisition strategy.

Information gathered under this effort will be reviewed as part of a market survey in support of the NGDS Increment 2 acquisition program planned to begin August 2014. 

CBMS-BSV is interested in collecting information from companies who are currently in the U.S. domestic healthcare market or are considering a future entry into that market who may have technologies or systems adaptable to military requirements for FDA-cleared diagnostics for human diseases caused by exposure to CBRN warfare threat agents and in support stakeholder agencies, potentially, endemic agents. 

Applications for these technologies and systems include: 

Point of Care diagnostics in a CLIA-waived setting 
Use at small clinical laboratories providing centralized support to fixed site and mobile hospitals less than 200 beds 
Individual self-testing
Advanced sample preservation approaches for sample transport under austere conditions and remote analysis up to 7 days after sample collection
Reliable self-sampling techniques for a broad range of clinical sampling types to support remote analysis
HIPAA-Compliant communications and data processing tools supporting remote data analysis/interpretation of point of care sample analyses  
Non-invasive, very low invasive population screening tools to identify people who may benefit from follow-on diagnostic testing

The system is envisioned to be man portable, safe for use with highly pathogenic agents, and provide a single sample time to result within 20 minutes. The system must be FDA cleared for in-vitro diagnostics or be sufficiently mature to begin FDA Clinical Trials by January 2016.

Respondents are invited to provide materials related to their capabilities to fulfill any or all of the requirements specified in this RFI. Respondents are further requested to indicate their level of interest and capability to fulfill the entire scope of the effort, or to fulfill a limited aspect of the effort as part of a team or as a subcontractor with another organization.

Further details are available under Identification of Diagnostic Devices and Enabling Technologies and Systems (W911QY-13-RFI-NGDSI2). The response deadline is May 30, 2013.

About CBMS

The Chemical Biological Medical Systems (CBMS) Joint Project Management Office (JPMO), under the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), is the DOD organization responsible for the advanced development, procurement, fielding, and sustaining of medical treatment, prophylactic, and diagnostic capabilities against chemical, biological, radiological, and nuclear (CBRN) warfare agents. 

Tags: JPEO-CBRNDMobile ResponsePOC DiagnosticsRFIRuggedized

Related Posts

two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy